<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329235</url>
  </required_header>
  <id_info>
    <org_study_id>Cangzhou Central Hospital</org_study_id>
    <nct_id>NCT03329235</nct_id>
  </id_info>
  <brief_title>Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Intraosseous With Intra-articular Injection of Platelet Rich Plasma Versus Hyaluronic Acid in Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cangzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cangzhou Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the efficacy of treatment in three groups of patients&#xD;
      with knee osteoarthritis (OA) given a combination of intraosseous with intra-articular&#xD;
      injection of platelet rich plasma (PRP), intra-articular injection of PRP and a single&#xD;
      application of hyaluronic acid (HA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods Eighty-six patients from January 2015 to June 2015 with grade II to grade III knee&#xD;
      osteoarthritis according to the Kellgren-Lawrence classification were randomly divided into 3&#xD;
      groups to receive either PRP or HA. Group A received intra-articular injection of PRP 2 ml&#xD;
      combination with medial tibial plateau and medial femoral condyle injection of PRP 2 ml (once&#xD;
      more 2 weeks later). Group B were treated with 2 ml of PRP intra-articular injection every 14&#xD;
      days for a total of two injections. Group C received intra-articular injection of hyaluronic&#xD;
      acid 2 ml every 7 days for five injections. All patients were evaluated by the Visual&#xD;
      Analogue Scale (VAS) and the Western Ontario and McMaster Universities (WOMAC) score before&#xD;
      the treatment and at 1st, 3rd, 6th, 12th and 18th months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC scores</measure>
    <time_frame>At the 18th month</time_frame>
    <description>The evaluation was performed with WOMAC, which were recorded on a five-point Likert scale scoring, with a response of &quot;none&quot; scored as 0, &quot;mild&quot; as 1, &quot;moderate&quot; as 2, &quot;severe&quot; as 3 and &quot;extreme&quot; as 4.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Intraosseous and intra-articular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of PRP 2 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-articular PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection PRP 2 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-articular injection of HA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of HA 2 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRP</intervention_name>
    <description>platelet rich plasma</description>
    <arm_group_label>Intraosseous and intra-articular</arm_group_label>
    <arm_group_label>intra-articular PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HA</intervention_name>
    <description>hyaluronic acid</description>
    <arm_group_label>Intra-articular injection of HA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral symptomatic knee with pain for at least 1 month or swelling.&#xD;
&#xD;
          -  Radiographic findings of knee degeneration (Kellgren-Lawrence score of II - III).&#xD;
&#xD;
          -  Age 40-73 years.&#xD;
&#xD;
          -  Body mass index (BMI) 18-32.5).&#xD;
&#xD;
          -  Knee stability without a severe trauma history.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral knee osteoarthritis indicative of treatment for both knees.&#xD;
&#xD;
          -  Kellgren-Lawrence score greater than III.&#xD;
&#xD;
          -  BMI &gt;32.&#xD;
&#xD;
          -  Age &gt;73 years.&#xD;
&#xD;
          -  Systemic autoimmune rheumatic diseases and blood disorders.&#xD;
&#xD;
          -  Active immunosuppressive or anticoagulant therapy.&#xD;
&#xD;
          -  Intra-articular injection to the knee within the previous 1 year or previous joint&#xD;
             infection.&#xD;
&#xD;
          -  use of corticosteroids for 3 weeks before the procedure.&#xD;
&#xD;
          -  use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the 3 weeks before treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

